Evolving Treatment Strategies for Recurrent Low-Grade Serous Ovarian Cancer
Expert oncologist Premal Thaker, MD, MS, reviews the current treatment landscape for recurrent low-grade serous ovarian cancer and considers the respective roles of various targeted agents in this setting.
Cervical Cancer Management: Looking Toward the Future of Care
Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.
Metastatic Cervical Cancer: Practical Considerations for Tisotumab Vedotin Use
Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.
Dr. Thaker on the Importance of Surveying Patients on Unmet Needs in Ovarian Cancer
Premal Thaker, MD, MS, discusses the importance of surveying patients on unmet needs in ovarian cancer.
Metastatic Cervical Cancer: ADC Adverse Event Management
Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.
Tisotumab Vedotin: A Second-Line ADC Approval in Metastatic Cervical Cancer
Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.
Metastatic Cervical Cancer: Moving Immune Checkpoint Inhibition to the Front Line
Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.
Second-Line Immune Checkpoint Inhibition in Metastatic Cervical Cancer
An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.
Unmet Needs in Second-Line Therapy for Metastatic Cervical Cancer
Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.
Metastatic Cervical Cancer: Interpreting Data From KEYNOTE-826
Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.
KEYNOTE-826: Immune Checkpoint Inhibition in Metastatic Cervical Cancer
Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.
Chemotherapy and Antiangiogenesis Therapy in Metastatic Cervical Cancer
Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.
Ongoing Clinical Trials in Locally Advanced Cervical Cancer
Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.
Locally Advanced Cervical Cancer: Interpreting the OUTBACK Trial
Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.
Locally Advanced Cervical Cancer: Surgery and Standard of Care Therapy
Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.
What is the Current Role of Biomarker Testing in Cervical Cancer?
The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.
Role of HPV Vaccination and Screening to Prevent Cervical Cancer
A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.
Understanding the Biology and Staging of Cervical Cancer
Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.
Dr. Thaker on EGEN-001 Combined With Doxorubicin for Ovarian Cancer
Premal H. Thaker, MD, MS, discusses a phase I study examining the combination of EGEN-001 and doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512